These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24824861)

  • 1. Development of rabbit monoclonal antibodies for detection of alpha-dystroglycan in normal and dystrophic tissue.
    Fortunato MJ; Ball CE; Hollinger K; Patel NB; Modi JN; Rajasekaran V; Nonneman DJ; Ross JW; Kennedy EJ; Selsby JT; Beedle AM
    PLoS One; 2014; 9(5):e97567. PubMed ID: 24824861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new monoclonal antibody DAG-6F4 against human alpha-dystroglycan reveals reduced core protein in some, but not all, dystroglycanopathy patients.
    Humphrey EL; Lacey E; Le LT; Feng L; Sciandra F; Morris CR; Hewitt JE; Holt I; Brancaccio A; Barresi R; Sewry CA; Brown SC; Morris GE
    Neuromuscul Disord; 2015 Jan; 25(1):32-42. PubMed ID: 25387694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
    Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
    Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. biAb Mediated Restoration of the Linkage between Dystroglycan and Laminin-211 as a Therapeutic Approach for α-Dystroglycanopathies.
    Gumlaw N; Sevigny LM; Zhao H; Luo Z; Bangari DS; Masterjohn E; Chen Y; McDonald B; Magnay M; Travaline T; Yoshida-Moriguchi T; Fan W; Reczek D; Stefano JE; Qiu H; Beil C; Lange C; Rao E; Lukason M; Barry E; Brondyk WH; Zhu Y; Cheng SH
    Mol Ther; 2020 Feb; 28(2):664-676. PubMed ID: 31843448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy.
    Beedle AM; Turner AJ; Saito Y; Lueck JD; Foltz SJ; Fortunato MJ; Nienaber PM; Campbell KP
    J Clin Invest; 2012 Sep; 122(9):3330-42. PubMed ID: 22922256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.
    Martin PT; Shelton GD; Dickinson PJ; Sturges BK; Xu R; LeCouteur RA; Guo LT; Grahn RA; Lo HP; North KN; Malik R; Engvall E; Lyons LA
    Neuromuscul Disord; 2008 Dec; 18(12):942-52. PubMed ID: 18990577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site mapping and characterization of O-glycan structures on alpha-dystroglycan isolated from rabbit skeletal muscle.
    Stalnaker SH; Hashmi S; Lim JM; Aoki K; Porterfield M; Gutierrez-Sanchez G; Wheeler J; Ervasti JM; Bergmann C; Tiemeyer M; Wells L
    J Biol Chem; 2010 Aug; 285(32):24882-91. PubMed ID: 20507986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dystroglycan glycosylation and its role in matrix binding in skeletal muscle.
    Martin PT
    Glycobiology; 2003 Aug; 13(8):55R-66R. PubMed ID: 12736199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant glycosylation of alpha-dystroglycan causes defective binding of laminin in the muscle of chicken muscular dystrophy.
    Saito F; Blank M; Schröder J; Manya H; Shimizu T; Campbell KP; Endo T; Mizutani M; Kröger S; Matsumura K
    FEBS Lett; 2005 Apr; 579(11):2359-63. PubMed ID: 15848172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.
    Foltz SJ; Luan J; Call JA; Patel A; Peissig KB; Fortunato MJ; Beedle AM
    Skelet Muscle; 2016; 6():20. PubMed ID: 27257474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosylation with ribitol-phosphate in mammals: New insights into the O-mannosyl glycan.
    Manya H; Endo T
    Biochim Biophys Acta Gen Subj; 2017 Oct; 1861(10):2462-2472. PubMed ID: 28711406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders].
    Toda T
    Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The modulation of skeletal muscle glycosylation as a potential therapeutic intervention in muscular dystrophies.
    Brockington M; Muntoni F
    Acta Myol; 2005 Dec; 24(3):217-21. PubMed ID: 16629056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgenic overexpression of LARGE induces α-dystroglycan hyperglycosylation in skeletal and cardiac muscle.
    Brockington M; Torelli S; Sharp PS; Liu K; Cirak S; Brown SC; Wells DJ; Muntoni F
    PLoS One; 2010 Dec; 5(12):e14434. PubMed ID: 21203384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant glycosylation of alpha-dystroglycan and congenital muscular dystrophies.
    Endo T
    Acta Myol; 2005 Oct; 24(2):64-9. PubMed ID: 16550917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dystroglycan linkage and muscular dystrophy].
    Shimizu T
    Rinsho Shinkeigaku; 2002 Nov; 42(11):1091-4. PubMed ID: 12784674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain alpha-dystroglycan displays unique glycoepitopes and preferential binding to laminin-10/11.
    McDearmon EL; Combs AC; Sekiguchi K; Fujiwara H; Ervasti JM
    FEBS Lett; 2006 Jun; 580(14):3381-5. PubMed ID: 16709410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and Galgt2 transgenic mouse skeletal muscle.
    Yoon JH; Johnson E; Xu R; Martin LT; Martin PT; Montanaro F
    J Proteome Res; 2012 Sep; 11(9):4413-24. PubMed ID: 22775139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunodetection of partially glycosylated isoforms of alpha-dystroglycan by a new monoclonal antibody against its beta-dystroglycan-binding epitope.
    Pavoni E; Sciandra F; Barca S; Giardina B; Petrucci TC; Brancaccio A
    FEBS Lett; 2005 Jan; 579(2):493-9. PubMed ID: 15642365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dystrophic phenotype induced in vitro by antibody blockade of muscle alpha-dystroglycan-laminin interaction.
    Brown SC; Fassati A; Popplewell L; Page AM; Henry MD; Campbell KP; Dickson G
    J Cell Sci; 1999 Jan; 112 ( Pt 2)():209-16. PubMed ID: 9858474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.